Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia

Kuliszkiewicz‐Janus, Małgorzata; Tuz, Mariusz Adam; Baczyński, Stanisław

doi:10.1016/j.bbalip.2005.08.019

Cited by 28 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has also been observed in other tumor cells (Jantscheff et al, unpublished data) and this effect can be discussed as one possible cause for the strongly reduced LysoPC plasma amounts observed in patients with advanced metastatic cancer (17)(18)(19)(20)(21). In addition, a radical shift in tumor cell membrane FA composition toward saturated FAs was observed, culminating between 48 and 72 hours without increasing after further LysoPC exposure (Fig.…”

Section: Discussionmentioning

confidence: 57%

“…The FA composition of plasma LysoPC in healthy individuals is comparable with that of total plasma PL; our unpublished studies confirm that more than 31% of the plasma LysoPC molecules carry unsaturated FAs. Various clinical observations have shown that plasma LysoPC levels are often decreased in advanced metastatic cancer patients (17)(18)(19)(20), especially when weight loss and inflammatory processes occur (21). This finding suggests a deregulation of the aforementioned LysoPC balance by malignant tumors and clearly indicates the potential importance of LysoPC in metastatic and cachectic processes.…”

Section: Introductionmentioning

confidence: 64%

“…These enzymes mostly hydrolyze lipoprotein-associated PL, both at the SN À1 as well as the SN À2 position (11)(12)(13)(14)(15)(16), thereby contributing to a pool of LysoPL that represents about one tenth of the total amount of plasma PL (9). The concentration of LysoPC was found to be constant in blood plasma of healthy persons, ranging from 200 to 300 mmol/L (16) or 300 to 400 mmol/L (17,18), suggesting a sensitive balance between generation and removal of LysoPC (e.g., by cellular uptake). The FA composition of plasma LysoPC in healthy individuals is comparable with that of total plasma PL; our unpublished studies confirm that more than 31% of the plasma LysoPC molecules carry unsaturated FAs.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo

Jantscheff

Schlesinger

Fritzsche

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Lysophosphatidylcholine (LysoPC) is an important intermediate in degradation and biosynthesis of phosphatidylcholine (PC). Reduced plasma LysoPC levels observed in patients with advanced cancer indicate a deregulation of LysoPC metabolism in metastasis. Recent data showed strong antimetastatic effects of liposomes consisting of saturated PC in a murine pancreatic metastasis model. LysoPC, generated from saturated PC after accumulation of the liposomes in tumor tissue, might be contributing to these effects. Examining effects of high local concentrations of saturated LysoPC and investigating potential molecular mechanisms, fast removal of saturated LysoPC from medium by murine B16.F10 melanoma cells and radical shifts in tumor cell membrane fatty acid (FA) composition toward saturated FAs were observed in vitro. Scanning electron microscopy revealed remarkable morphologic surface changes of LysoPC-treated tumor cells, probably causing their impaired migratory ability on fibronectin. A LysoPC concentration exceeding a threshold of about 400 mmol/L, slightly above physiologic levels, strongly reduced VLA-4-mediated binding of B16.F10 cells to VCAM-1 as well as P-selectin-dependent interaction with activated platelets, although expression levels were not altered. These findings were reflected in a syngenic intravenous lung invasion model using repeatedly ex vivo LysoPC-treated (450 mmol/L) B16.F10 cells, resulting in significantly reduced lung metastasis-like lesions (À48.3%, P ¼ 0.006). Prior application of 50 IU unfractionated heparin further reduced lung invasion (À81.6%, P ¼ 0.043). Our work shows for the first time that saturated LysoPC in high concentrations reduces melanoma cell adhesion in vitro and hematogeneous dissemination in vivo by direct ex vivo tumor cell targeting.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Introductionmentioning

confidence: 64%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo

Jantscheff

Schlesinger

Fritzsche

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…The 31 P MRS spectra were obtained using an AMX Bruker 300 spectrometer. The methods were described previously in detail [10][11][12]. The chemical shift of the PAF peak in the 31 P NMR spectra of the investigated phospholipid extracts (from the plasma, PBMC or BMMC) equaled 0.14 ppm in Brought to you by | MIT Libraries Authenticated Download Date | 5/11/18 6:53 PM reference to 85% orthophosphoric acid.…”

Section: Methodsmentioning

confidence: 99%

“…In nanomolar concentrations, this phospholipid plays a significant role in the activation of leukocytes and macrophages [5,6], platelet aggregation [7], cell adhesiveness [8], angiogenesis [9] and other biological events. In our last study, we applied 31 P MRS to analyze phospholipid changes in the plasma of patients with AL [10,11], and to analyze the phospholipid composition of normal human PBMC [12]. The aim of this investigation was to evaluate the changes in PAF concentrations in the plasma, PBMC and BMMC of patients with acute lymphoblastic leukemia and acute myeloblastic leukemia.…”

Section: Introductionmentioning

confidence: 99%

Platelet-activating factor changes in phospholipid extracts from the plasma, peripheral blood mononuclear cells and bone marrow mononuclear cells of patients with acute leukemia — A 31P MRS in vitro study

Kuliszkiewicz‐Janus¹,

Tuz²,

Kiełbiński

et al. 2008

Cellular and Molecular Biology Letters

Self Cite

View full text Add to dashboard Cite

Abstract:The aim of this investigation was to evaluate the changes in PAF concentrations in the plasma, PBMC and BMMC of patients with acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML). The plasma was from 23 healthy volunteers (HV) and 44 patients with AL (16 ALL, 28 AML). The PBMC were from 15 HV and 55 patients with AL (18 ALL, 37 AML), and the BMMC from 40 patients with AL (11 ALL, 29 AML). Methanol-chloroform phospholipid extraction from 60 x 10 6 cells (PBMC or BMMC) was performed according to a modified version of Folch's method. 31 P MRS data was obtained on an AMX 300 Bruker spectrometer (7.05 T). The PAF concentration in the plasma of the patients with ALL or AML was lower than that for the healthy volunteers. The PAF concentration in the plasma of the patients with ALL did not differ significantly from that of the patients with AML. In the case of both the PBMC and BMMC, the PAF concentration was significantly diminished in patients with ALL relative to the concentration for those with AML and for the healthy volunteers. No differences were observed in the PAF concentrations for the AML patients and the healthy volunteers.

show abstract

Low serum cholesterol levels predict inferior prognosis and improve NCCN‐IPI scoring in diffuse large B cell lymphoma

Gao

Liang

Wang

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Low circulating cholesterol concentration is associated with elevated cancer incidence and mortality. However, the association between cholesterol levels and diffuse large B cell lymphoma (DLBCL) remains unknown. The aim of our study was to evaluate the prognostic value of serum lipid profile in DLBCL. Five hundred and fifty enrolled subjects with detailed serum lipid levels at diagnosis of DLBCL were randomly divided into a training set (n = 367) and a validation set (n = 183) (ratio, 2:1). Multivariate Cox regression analyses screened the prognostic factors associated with progression-free survival (PFS) and overall survival (OS). Performances of models were compared using C-index and area under the curve in internal and external validation. The results showed that decreased levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were associated with unfavorable PFS and OS in the rituximab era, and concurrently low HDL-C together with low LDL-C was an independent prognostic indicator for both PFS and OS. Patients achieving complete remission or partial remission after 6-8 circles of chemotherapies had significantly increased cholesterol levels compared to the levels at DLBCL diagnosis, and HDL-C or LDL-C elevations were correlated with better survival. Furthermore, the predictive and discriminatory capacity of the National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) together with low cholesterol levels was superior to NCCN-IPI alone both in the training and validation set. In conclusion, serum cholesterol levels are simple and routinely tested parameters, which may be good candidates for predicting prognosis in the future clinical practice of DLBCL.

show abstract

Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia

Cited by 28 publications

References 19 publications

Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo

Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo

Platelet-activating factor changes in phospholipid extracts from the plasma, peripheral blood mononuclear cells and bone marrow mononuclear cells of patients with acute leukemia — A 31P MRS in vitro study

Low serum cholesterol levels predict inferior prognosis and improve NCCN‐IPI scoring in diffuse large B cell lymphoma

Contact Info

Product

Resources

About